Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi

Journal of Extra-Corporeal Technology

Volumn 39, Issue 2, 2007, Pages 81-86

  Hellstern, Peter ^a   Bach, Juergen ^a   Simon, Melanie ^a   Saggau, Werner ^a  

^a Academic City Hospital   (Germany)

Author keywords

Activated clotting time; Anticoagulation; Cardiopulmonary bypass; Chromogenic substrate heparin assay; Heptest POC Hi

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; ANTICOAGULANT AGENT; CHROMOGENIC SUBSTRATE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONITORING; OBSERVATIONAL STUDY; POINT OF CARE TESTING; PROTEIN BLOOD LEVEL; RELIABILITY; STATISTICAL SIGNIFICANCE; BLOOD CLOTTING TEST; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DRUG MONITORING; EVALUATION; HOSPITAL INFORMATION SYSTEM; REPRODUCIBILITY;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CARDIOPULMONARY BYPASS; CHROMOGENIC COMPOUNDS; DRUG MONITORING; FACTOR XA; HEPARIN; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; POINT-OF-CARE SYSTEMS; REPRODUCIBILITY OF RESULTS; WHOLE BLOOD COAGULATION TIME;

EID: 35248828591     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Linden MD. The hemostatic defect of cardiopulmonary bypass. J Thromb Thrombolysis. 2003;16:129-47.
2. Jones K, Nasrallah F, Darling E, Clay N, Searles B. The in vitro effects of aprotinin on twelve different ACT tests. J Extra Corpor Technol. 2004;36:51-7.
3. Swartz MF, Fink GW, Searles B. Aprotinin and hemostasis monitoring concerns during cardiac surgery. J Extra Corpor Technol. 2004;36:375-83.
4. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994;108:1076-82.
5. Hardy JF, Bélisle S, Robitaille D, Perrault J, Roy M, Gagnon L. Measurement of heparin concentration in whole blood with the Hepcon/ HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg. 1996;112:154-61.
6. Despotis GJ, Joist JH, Goodnough LT, Santoro SA, Spitznagel E. Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements. J Thorac Cardiovasc Surg. 1997;113:611-3.
7. Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time. Perfusion. 2003;18:269-76.
8. Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res. 1976;8:413-6.
9. Yin ET, Wessler S, Butler J. Plasma heparin: A unique, practical, submicrogram-sensitive assay. J Lab Clin Med. 1973;81:298-310.
10. Yin ET. Method and compositions for heparin assays. US Patent 4,946,775.
11. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-10.
12. Bevan DH. Cardiac bypass haemostasis: Putting blood through the mill. Br J Haematol. 1999;104:208-19.
13. Culliford AT, Gitel SN, Starr N, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg. 1981;193:105-11.
14. Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994;108:1076-82.
15. Hendrice C, Schmartz D, Pradier O. Effects of aprotinin on blood loss, heparin monitoring tests, and heparin doses in patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 1995;9:245-9.
16. Gravlee GP, Brauer SD, Roy R, et al. Predicting the pharmacodynamics of heparin: a clinical evaluation of the Hepcon system 4. J Cardiothorac Anesth. 1987;1:379-87.
17. Gravlee GP, Haddon WS, Rothberger HK, et al. Heparin dosing and monitoring for cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990;99:518-27.
18. Hansen R, Koster A, Kukucka M, Mertzlufft F, Kuppe H. A quick anti-Xa-activity-based whole blood coagulation assay for monitoring unfractionated heparin during cardiopulmonary bypass: A pilot investigation. Anesth Analg. 2000;91:533-8.
19. Beholz S, Grubitzsch H, Bergmann B, Wollert HG, Eckel L. Hemostasis management by use of Hepcon/HMS™: Increased bleeding without increased need for blood transfusion. Thorac Cardiovasc Surg. 1999;47:322-7.
20. Gray E, Walker AD, Mulloy B, Barrowcliffe TW. A collaborative study to establish the 5th International standard for unfractionated heparin. Thromb Haemost. 2000;84:1017-22.